Myeloma UK news
Findings have been published from the MUK six clinical trial, a trial conducted as part of the Myeloma UK Clinical Trial Network. Myeloma UK Research Director, Simon Ridley, explains how the findings could help myeloma patients in the future.
Myeloma UK has voiced concerns about proposals to introduce a £20m “budget impact threshold” for new medicines approved by the National Institute for Health and Care Excellence (NICE). These proposals were set out in a joint consultation issued by NHS England and NICE. Currently there are no specific concerns about particular myeloma treatments being affected by the proposed threshold.
After 20 years of outstanding service, Eric Low has announced that he is moving on from his post as Chief […]
Myeloma UK has been commended for the innovative use of technology to help support people affected by myeloma at the […]
Award-winning actress, Maureen Lipman has donated a limited number of signed prints from her new book to help increase awareness of myeloma and raising funds for Myeloma UK.
Myeloma UK has been hearing from the families, friends and carers of myeloma patients as we publish findings from a […]
Imnovid (pomalidomide) in combination with dexamethasone, has now been approved by the National Institute for Health and Care Excellence (NICE) […]
The Myeloma UK team are gearing up for the final Patient and Family Myeloma Infoday of the year, taking place […]
Ensuring earlier diagnosis and routine access to a clinical nurse specialist are two key areas highlighted by Myeloma UK on […]